How academic researchers, industry
and patients collaborate in order to fight Type 1 Diabetes.
INNODIA is a global partnership between 31 academic institutions, 6 industrial partners, a small sized enterprise and 2 patient organizations, bringing their knowledge and experience together with one common goal: "To fight type 1 diabetes".
The project runs under the framework of the Innovative Medicines Initiative – Joint Undertaking (IMI-JU) with a dedicated governance structure ensuring close interaction, communication and adherence to the objectives and deliverables of the consortium. Importantly, INNODIA is closely guided by the patients themselves, through the Patient Advisory Committee, consisting of a group of type 1 diabetes patients and parents, which give continuous feedback on the concept of INNODIA and development of protocols, and are crucial in disseminating the goals of INNODIA to the public.
INNODIA examines samples and data from newly diagnosed patients with type 1 diabetes and unaffected first degree relatives throughout Europe.
The recruitment target for newly diagnosed people with T1D has now been reached!
INNODIA is very thankful for all people with T1D who contributed to the progress in the project.
In the next phase; these collected samples and data will be examined in great detail.
We do however keep encouraging relatives of people with type 1 diabetes to take part in the study. In INNODIA, we can evaluate the risk in a more precise way by determination of autoantibodies in the blood. Early detection of T1D onset can prevent serious complications and participation into clinical studies to arrest disease progression is possible. Further follow-up is provided if they are at increased risk.
INNODIA is expanding
The project now also welcomes ALL autoantibody positive people in the general population with an increased risk of developing type 1 diabetes, detected through screening programs other than INNODIA. Even those without a family member with T1D.
To take part in this initiative, please consult our map to select a Center most nearby.
Thanks to the INNODIA research we will be able to better understand the relationship between changes in β-cell function, immune profiles, genetic and environmental factors and their role in the onset of the disease.
From the start, another major goal of INNODIA, was to undertake clinical intervention studies. With those trials, we want to halt the further decline in beta cell functionality in people with newly diagnosed T1D, addressing the immune system or the beta cells by different treatment modalities. In 2020 INNODIA started 4 clinical trials and more are coming.
Here again, pharmaceutical companies being part of INNODIA join forces with leading academic clinical researchers to prove the effectiveness of these potential new therapeutic agents.